SCHEMBL699304

SCHEMBL699304

CC(C)(C)CC(C)(C)c1ccc(-c2cccc(C(=O)O)c2O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HNF4A P41235 1/20 0.58
SHBG P04278 1/20 0.46
CYP3A4 P08684 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
PRKAB2 O43741 2/20 0.39
PRKAG1 P54619 2/20 0.39
PRKAA2 P54646 2/20 0.39
PRKAA1 Q13131 2/20 0.39
PRKAG3 Q9UGI9 2/20 0.39
PRKAG2 Q9UGJ0 2/20 0.39
PRKAB1 Q9Y478 2/20 0.39
MYC P01106 1/20 0.39
ALOX15 P16050 1/20 0.39
PTPN1 P18031 3/20 0.38
PTPN2 P17706 1/20 0.38
PTPN6 P29350 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL294262 0.84 HNF4A (0.67) HNF4AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL11231182 0.83 SHBG (0.46) HNF4ASHBGCYP3A4SMN1; SMN2HSD17B10
SCHEMBL8672552 0.79 HNF4A (0.51) HNF4ACYP3A4SMN1; SMN2HSD17B10KDM4E
SCHEMBL1129606 0.78 PTPN1 (0.55) HNF4ASHBGHSD17B10PTPN1PTPN2
SCHEMBL659867 0.76 ALDH1A1 (0.49) HNF4ASHBGCYP3A4SMN1; SMN2HSD17B10
SCHEMBL9786926 0.75 HNF4A (0.92) HNF4AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL73041 0.75 HNF4A (1.00) HNF4ASMN1; SMN2HSD17B10KDM4EALDH1A1
SCHEMBL29662951 0.75 HNF4A (1.00) HNF4ASMN1; SMN2HSD17B10KDM4EALDH1A1
SCHEMBL7089020 0.75 ALDH1A1 (0.47) HNF4ASHBGCYP3A4SMN1; SMN2HSD17B10
SCHEMBL647962 0.74 SHBG (0.56) SHBGCYP3A4SMN1; SMN2HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882571-B1 POLYOLEFIN-COVERED STEEL PIPE POSSESSING EXCELLENT RESISTANCES TO THERMALLY OXIDATIVE DETERIORATION AND WEATHERING AND PROCESS FOR MANUFACTURING THE SAME JFE STEEL CORP (JP) 2006-01-04 EP claimed
US-20260117044-A1 PHENOLIC COMPOUND, ORGANIC MATERIAL STABILIZER, RESIN COMPOSITION, AND METHOD FOR STABILIZING ORGANIC MATERIAL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2026-04-30 US disclosed
EP-4180482-B1 MOISTURE-CURABLE COMPOSITION NITTO KASEI CO LTD (JP) 2025-12-03 EP disclosed
EP-4650401-A1 PROCESSING STABILIZER, RESIN COMPOSITION, AND ORGANIC MATERIAL STABILIZING METHOD Sumitomo Chemical Company, Limited (JP) 2025-11-19 EP disclosed
US-20250171476-A1 PROCESS STABILIZER, ORGANIC MATERIAL COMPOSITION, AND METHOD FOR STABILIZING ORGANIC MATERIAL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2025-05-29 US disclosed
EP-4488337-A1 PROCESS STABILIZER, ORGANIC MATERIAL COMPOSITION, AND METHOD FOR STABILIZING ORGANIC MATERIAL Sumitomo Chemical Company, Limited (JP) 2025-01-08 EP disclosed
US-20240166672-A1 PHOSPHOROUS ESTER COMPOUND, METHOD FOR PRODUCING SAME AND USE APPLICATION FOR SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2024-05-23 US disclosed
EP-4371988-A1 PHENOLIC COMPOUND, ORGANIC MATERIAL STABILIZER, RESIN COMPOSITION, AND METHOD FOR STABILIZING ORGANIC MATERIAL Sumitomo Chemical Company, Limited (JP) 2024-05-22 EP disclosed
EP-4317166-A1 PHOSPHOROUS ESTER COMPOUND, METHOD FOR PRODUCING SAME, AND USE APPLICATION FOR SAME Sumitomo Chemical Company Limited (JP) 2024-02-07 EP disclosed
EP-4180482-A1 MOISTURE-CURABLE COMPOSITION Nitto Kasei Co., Ltd. (JP) 2023-05-17 EP disclosed
US-20030005621-A1 Candle wax stabilized with morpholinones CIBA SPECIALTY CHEMICALS CORP. 2003-01-09 US disclosed
US-20030000128-A1 Candle wax stabilized with oxazolidines CIBA SPECIALTY CHEMICALS CORP. 2003-01-02 US disclosed
US-20030000130-A1 Candle wax stabilized with piperazinones CIBA SPECIALITY CHEMICALS CORP. 2003-01-02 US disclosed
US-20020194776-A1 Candle wax stabilized with imidazolidines CIBA SPECIALTY CHEMICALS CORP. 2002-12-26 US disclosed
US-20020194777-A1 Candle wax stabilized with piperazinones CIBA SPECIALTY CHEMICALS CORP. 2002-12-26 US disclosed
WO-2002079313-A1 STABILIZED CANDLE WAX CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-10-10 WO disclosed
US-6306502-B1 COMPOSITION COMPRISING ULTRAVIOLET-CURABLE SILICONE, MONOMER MIXTURE COMPRISING TRIS((METH)ACRYLOYLOXYALKYL)ISOCYANURATE AND URETHANE POLY(METH)ACRYLATE HAVING ALICYCLIC SKELETON, PHOTOPOLYMERIZATION INITIATOR MITSUBISHI RAYON CO., LTD. (JP) 2001-10-23 US disclosed
EP-0869154-A1 COATING COMPOSITION FORMING WEAR-RESISTANT COAT AND ARTICLE COVERED WITH THE COAT MITSUBISHI RAYON CO., LTD. (JP) 1998-10-07 EP disclosed
EP-0227922-A2 Colourfast leisure and sports equipment HOECHST AKTIENGESELLSCHAFT (DE) 1987-07-08 EP disclosed
US-4404355-A AROMATIC ONIUM SALT AND COPPER COMPLEX AS CATALYSTS; PHOTOSTABILITY; CASTINGS; PROTECTIVE COATINGS CIBA-GEIGY CORPORATION (US) 1983-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260117044-A1 PHENOLIC COMPOUND, ORGANIC MATERIAL STABILIZER, RESIN COMPOSITION, AND METHOD FOR STABILIZING ORGANIC MATERIAL PIEZO1, TERB1, RPA1 HNF4A 3586/4885SHBG 2769/4885CYP3A4 1425/4885
US-20240166672-A1 PHOSPHOROUS ESTER COMPOUND, METHOD FOR PRODUCING SAME AND USE APPLICATION FOR SAME EBPL, ACSL6, ACSL3 HNF4A 2026/4885SHBG 3641/4885CYP3A4 1171/4885
US-20250171476-A1 PROCESS STABILIZER, ORGANIC MATERIAL COMPOSITION, AND METHOD FOR STABILIZING ORGANIC MATERIAL APOL1, ATXN2L, CCNL2 HNF4A 3339/4885SHBG 4765/4885CYP3A4 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.